ADMA Biologics (NASDAQ:ADMA) Downgraded by Zacks Research to “Strong Sell”

ADMA Biologics (NASDAQ:ADMA) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Tuesday,Zacks.com reports.

Several other brokerages have also weighed in on ADMA. Canaccord Genuity Group cut their price objective on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Wall Street Zen lowered shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Finally, Mizuho cut their price objective on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $19.00.

ADMA Biologics Price Performance

NASDAQ ADMA opened at $7.92 on Tuesday. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 11.65 and a beta of 0.83. The company has a 50 day simple moving average of $10.04 and a 200-day simple moving average of $14.80. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93. ADMA Biologics has a 52-week low of $7.21 and a 52-week high of $22.37.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, meeting the consensus estimate of $0.19. The firm had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The company’s revenue for the quarter was down .3% on a year-over-year basis. During the same quarter last year, the firm earned $0.11 earnings per share. Equities research analysts predict that ADMA Biologics will post 0.84 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the transaction, the chief operating officer owned 466,600 shares of the company’s stock, valued at $7,292,958. This trade represents a 2.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jerrold B. Grossman purchased 12,500 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the transaction, the director owned 513,884 shares of the company’s stock, valued at approximately $4,116,210.84. This trade represents a 2.49% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On ADMA Biologics

A number of institutional investors have recently modified their holdings of ADMA. Rothschild Investment LLC raised its position in shares of ADMA Biologics by 373.8% in the third quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,495 shares during the period. Summit Securities Group LLC bought a new position in shares of ADMA Biologics in the fourth quarter valued at approximately $29,000. Western Wealth Management LLC bought a new position in shares of ADMA Biologics in the first quarter valued at approximately $31,000. Clearstead Advisors LLC raised its position in shares of ADMA Biologics by 55.7% in the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 795 shares during the period. Finally, iSAM Funds UK Ltd bought a new position in shares of ADMA Biologics in the third quarter valued at approximately $34,000. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.